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Relationships Among HIV Infection, Metabolic Risk
Factors, and Left Ventricular Structure and Function
William Todd Cade,1,2 Edgar Turner Overton,3 Kristin Mondy,3 Lisa de las Fuentes,4,5
Victor G. Davila-Roman,4,5 Alan D. Waggoner,4,5 Dominic N. Reeds,6 Sherry Lassa-Claxton,2
Melissa J. Krauss,7 Linda R. Peterson,5 and Kevin E. Yarasheski1,2

Abstract

Our objective was to determine if the presence of metabolic complications (MC) conveyed an additional risk for left
ventricular (LV) dysfunction in people with HIV. HIV + and HIV - men and women were categorized into four
groups: (1) HIV + with MC (43 – 7 years, n = 64), (2) HIV + without MC (42 – 7 years, n = 59), (3) HIV - with MC
(44 – 8 years, n = 37), or (4) HIV - controls without MC (42 – 8 years, n = 41). All participants underwent twodimensional (2-D), Doppler, and tissue Doppler echocardiography. Overall, the prevalence of systolic dysfunction
(15 vs. 4%, p = 0.02) and LV hypertrophy (9 vs. 1%, p = 0.03) was greater in HIV + than in HIV - participants.
Participants with MC had a greater prevalence of LV hypertrophy (10% vs. 1%). Early mitral annular velocity
during diastole was significantly ( p < 0.005) lower in groups with MC (HIV + /MC + : 11.6 – 2.3, HIV - /MC + :
12.0 – 2.3 vs. HIV + /MC - : 12.4 – 2.3, HIV - /MC - : 13.1 – 2.4 cm/s) and tended to be lower in groups with HIV
( p = 0.10). However, there was no interaction effect of HIV and MC for any systolic or diastolic variable. Regardless
of HIV status, participants with MC had reduced LV diastolic function. Although both the presence of MC and HIV
infection were associated with lower diastolic function, there was no additive negative effect of HIV on diastolic
function beyond the effect of MC. Also, HIV was independently associated with lower systolic function. Clinical
monitoring of LV function in individuals with metabolic risk factors, regardless of HIV status, is warranted.

Introduction

L

eft ventricular (LV) dysfunction is common in latestage acquired immune deficiency syndrome (AIDS),1,2
but since the advent of combination antiretroviral therapy
(cART) the incidence of AIDS-related cardiomyopathy has
significantly declined.3,4 Despite these improvements, evidence from both industrialized5–12 and developing countries9
indicates that the prevalence of subclinical LV dysfunction in
individuals with well-controlled HIV infection may approach
50%12,13 and may represent a newly recognized comorbid
condition.14,15
Mechanisms for subclinical LV function abnormalities in
HIV are unclear. The HIV virus and its related proteins16,17
may play a role in LV dysfunction; however, other factors also
likely contribute to impaired contractility.15 HIV infection and
cART are associated with adverse metabolic risk factors or
complications, frequently referred to as HIV-related metabolic syndrome, that are related to increased risk for myo-

cardial infarction in individuals with HIV.18 This syndrome
includes insulin resistance,19,20 dyslipidemia,21,22 and central
fat accumulation,23,24 all characteristics of non-HIV-associated
metabolic syndrome, a condition associated with higher cardiovascular (CV) disease risk.25–27 In HIV - people, the metabolic syndrome is associated with an increased risk for CV
morbidity (including coronary artery disease and congestive
heart failure) and mortality.25 Recent evidence has also linked
metabolic risk factors to subclinical LV dysfunction in HIV individuals.25,26,28,29 LV dysfunction is an important predictor
of overall mortality in the general population.30
The objective of this study was to determine if the presence of metabolic risk factors/complications similar to the
metabolic syndrome in the general population conveys an
additional risk for LV dysfunction in men and women infected with HIV. We hypothesized that in participants with
HIV infection, metabolic risk factors present an additive risk
for LV systolic and diastolic dysfunction over HIV infection
alone.

1
Program in Physical Therapy, 2Division of Endocrinology, Metabolism, and Lipid Research, 3Division of Infectious Disease, 4Cardiovascular Imaging and Clinical Research Core Laboratory, 5Cardiovascular Division, 6Division of Geriatrics and Nutritional Science, and
7
Division of Biostatistics, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
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Materials and Methods
Participants
HIV-infected men and women were recruited from the
AIDS Clinical Trials Unit, the Infectious Diseases Clinics at
Washington University School of Medicine (WUSM), and the
surrounding metro St. Louis community. HIV - men and
women were recruited from the Division of Cardiology, the
Department of Radiology, and through a volunteer recruitment service at WUSM. Participants were categorized to one
of four groups: (1) HIV-positive participants currently taking
cART with three or more metabolic risk factors/metabolic
complications (MC), (HIV + /MC + ; n = 64), (2) HIV-positive
participants taking cART having one or no metabolic risk
factors/complications (HIV + /MC - ; n = 59), (3) HIV-negative
participants with three or more metabolic risk factors/complications (HIV - /MC + ; n = 37), or (4) HIV-negative healthy
controls with similar age, gender, and activity level with one
or no metabolic risk factors/complications (HIV - /MC - ;
n = 41). For both HIV + and HIV - groups, metabolic complications were defined according to a modification of the
amended National Cholesterol Education Program’s Adult
Treatment Panel III (ATP-III) guidelines and a definition of
HIV metabolic syndrome.
All participants with MC met three or more of the following
criteria: (1) body mass index (BMI) ‡ 30 kg/m2; (2) fasting
serum glucose ‡ 100 mg/dl OR fasting serum insulin
‡ 13 lU/ml OR use of glucose-lowering medication; (3) fasting serum triglyceride ‡ 150 mg/dl; (4) resting blood pressure: systolic ‡ 130 OR diastolic ‡ 85 mm Hg OR
antihypertensive therapy; and (5) low high-density lipoprotein (HDL) ( < 40 mg/dl in men or < 50 mg/dl in women)
(Fig. 1).31 Most of the prior research examined the prevalence
of the metabolic syndrome in HIV + individuals using the
traditional ATP-III criteria of impaired fasting glucose32–35;
however, others have used additional criteria36,37 to define
impaired fasting glucose. We included fasting insulin as a
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FIG. 1. Percent meeting individual component of metabolic
complication criteria. BMI, body mass index; IFG, impaired
fasting glucose; INS, plasma insulin; GluMed, glucoselowering medication; TG, triglyceride; HDL, high-density
lipoprotein; SBP, systolic blood pressure; DBP, diastolic
blood pressure; HTNMed, hypertension medication.

criterion for abnormal glucose metabolism because HIV infection is associated with fasting hyperinsulinemia but normal
glycemia, while typical metabolic syndrome (HIV - ) is associated with fasting hyperinsulinemia and hyperglycemia.24 In
addition, due to the known relationship between insulin resistance and diastolic dysfunction,38 we believed it was important to include a measure of fasting insulin in order not to
exclude participants who had insulin resistance but normal
fasting glucose.
BMI was used as a criterion for abnormal body composition as waist circumference (WC) was not available for all
participants. The World Health Organization defines abdominal adiposity as BMI > 30 kg/m2 in the definition of the
metabolic syndrome and abdominal adiposity is common in
HIV + adults, so it is likely a valid surrogate for WC. In addition, although unknown in HIV, the prevalence of the
metabolic syndrome in the general population is essentially
identical whether BMI or WC is used.39 While differences in
the prevalence of abdominal adiposity between HIV + and
HIV - individuals with the metabolic syndrome are not
clear,32,37 increased BMI is associated with a higher prevalence of ATP-III-defined metabolic syndrome in HIV + people suggesting that abdominal adiposity is an important
component of HIV-associated metabolic syndrome. Regardless, abdominal obesity was recently determined not to
be an obligatory criterion for the definition of the metabolic
syndrome.40
HIV-infected participants had been taking their current
cART regimen for ‡ 6 months (Table 1). For HIV + /MC + , 30
(47%) were on a protease inhibitor (PI)-based regimen, 24
(38%) were on a nonnucleoside reverse transcriptase inhibitor
(NNRTI)-based regimen, one (2%) was on both a PI- and
NNRTI-based regimen, one (2%) was on triple NRTI therapy,
two (3%) were not on therapy, and six (9%) were unknown
due to loss of contact. For HIV + /MC - , 27 (46%) were on a PIbased regimen, 29 (49%) were on an NNRTI-based regimen,
one (2%) was on triple NRTI therapy, one (2%) was not on
therapy, and one (2%) was unknown due to loss of contact.
There were no differences in the major types of NRTI between
HIV + /MC + and HIV + /MC - (zidovudine: 20 vs. 24%, lamivudine: 34 vs. 30%, tenofovir: 39 vs. 51%). Other types of
NRTI occurred in small percentages in each group. All HIVinfected participants had plasma HIV RNA that was undetectable ( < 400 copies/ml) except for nine HIV + /MC + and
eight HIV + /MC - participants who had viral loads of 401–
50,000 copies RNA/ml (Table 1). No participants had a current opportunistic infection or CD4 count below 200 cells/ll.
The duration of HIV infection and time on cART were similar
between groups (Table 1).
Participants were excluded if they consumed more than
three alcohol-containing beverages per week, were coinfected
with hepatitis C or B, reported using recreational drugs for 6
months prior to enrollment, had documented type 2 diabetes
or coronary artery disease, and were not weight stable (less
than 2% weight change in the 3 months prior to the study).
None of the participants participated regularly (more than
two times/week) in physical activities that would constitute
exercise training. HIV + /MC - had a higher percentage of
current tobacco users than the other groups (Table 1). The
Human Studies Committee at Washington University approved the study and all participants provided informed
consent prior to participation.
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Table 1. Demographic Characteristics of Study Participants
HIV Variable
Age (years)
Male, n (%)
African-American, n (%)
Other nonwhite, n (%)
CD4 (cells/ll)
Median viral load (copies/ml)
Median HIV duration (months)
Median cART use (months)
Current tobacco use, n (%)
Antiretroviral therapy, n (%)
NRTI
NNRTI
PI
Fusion
Medical therapy, n (%)
HTN
Lipid lowering

HIV +

MC (n = 41)

MC +
(n = 37)

MC (n = 59)

MC +
(n = 64)

42 – 6
35 (85)
14 (34)
0 (0)
N/A
N/A
N/A
N/A
10 (24)

44 – 8
33 (89)
7 (19)
0 (0)
N/A
N/A
N/A
N/A
10 (27)

42 – 7
45 (76)
31 (53)
0 (0)
515 – 206
UD (0–33,872)
133 (14–262)
71 (3–246)
25 (43)

43 – 7
53 (83)
29 (45)
2 (3)
537 – 260
UD (0–48,600)
121 (23–272)
73 (4–237)
14 (22)

N/A
N/A
N/A
NA

N/A
N/A
N/A
NA

6 (15)
3 (7)

16 (43)
10 (27)

56
26
32
0

(95)
(44)
(54)
(0)

4 (7)
2 (3)

60
29
39
2

(94)
(45)
(61)
(3)

15 (23)
16 (25)

p
0.739
0.433
0.005
—
—
—
—
0.064
—
—
—
—
< 0.001
< 0.001

HIV, human immunodeficiency virus; MC, metabolic complications; cART, combined antiretroviral therapy; UD, undetectable < 400
copies/ml; BMI, body mass index; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI,
protease inhibitor; Fusion, fusion inhibitor; HTN, hypertension.

Fasting blood chemistry, glucose tolerance,
and body composition
Upon enrollment, participants provided a comprehensive
medical history and underwent a physical examination,
fasting blood chemistry, complete blood cell count, plasma
HIV RNA quantification (Roche Amplicor HIV-1 Monitor,
Indianapolis, IN), and serum lipid, lipoprotein, and endocrine
profiles [insulin, triglycerides (TG), total-, LDL-, and HDLcholesterol]. Plasma analyses were performed as previously
described.41
Resting echocardiography
Indices of LV structure and function were measured by
two-dimensional (2-D), Doppler, and tissue Doppler imaging
(TDI) by a blinded echocardiographer. 2-D measurements
included LV volumes and end diastolic and end systolic
volumes from the apical four- and two-chamber views
(method of disks). LV ejection fractions were determined by
the biplane method and by the area-length method, respectively, normalized to body surface area.42 LV mass was measured by the 2-D-directed M-mode-derived cubed method.43
Pulsed wave Doppler (PWD) transmitral velocities were
obtained at the mitral leaflet tips according to established
guidelines.44 Indices of LV diastolic function include the peak
transmitral early diastolic (E) and late diastolic atrial (A) inflow
velocities, the ratio of the peak mitral E/A velocities, and the Ewave deceleration time.45 Isovolumic relaxation time was determined by measuring the time from the closure of the aortic
valve to the onset of mitral flow. Resting heart rate, systolic and
diastolic blood pressures, and mean arterial pressure were
measured at the time of echocardiography.
TDI was determined by the placement of a 3-mm sample
volume at the lateral and septal mitral annulus in the four-

chamber view. Systolic (S¢) and early diastolic (E¢) myocardial
wall velocities from the two sites were averaged to derive S¢
and E¢.46 Measurement at the lateral and septal annulus has
been shown to have high specificity for indicating relatively
load-independent impaired relaxation.47,48 Measurements
represent the average of three to five cycles. We chose these
diastolic measures because the E/A ratio is a load-dependent
measure of the pressure gradient between the left atrium and
LV (influenced by alterations in relaxation); mitral valve annular velocity (E¢) is a relatively load-independent measure of
LV relaxation; isovolumic relaxation time is a load-dependent
measure of LV relaxation; E-wave deceleration time is an indirect measure of LV stiffness; and E/E¢ is an estimate of LV
filling pressures.47
Systolic dysfunction was defined by the LV ejection fraction
categorized as normal ( ‡ 55%), mildly decreased (45–54%),
moderately decreased (35–44%), and severely depressed
( < 35%) as defined by Mondy et al.14 Diastolic dysfunction was
defined on the basis of Doppler peak early (E) and late (A)
diastolic mitral inflow velocity, mitral inflow deceleration time,
and mitral annular velocity (E¢) averaged from the lateral wall
and septum.49,50 Left ventricular hypertrophy was determined
by M-mode echocardiography values for LV mass index ‡ 127
for men and ‡ 100 for women.43
Statistics
Differences in demographic variables among the four
groups (HIV + /MC + , HIV + /MC - , HIV - /MC + , and HIV - /
MC - ) were tested using Fisher’s exact tests for categorical
variables and one-way analysis of variance (ANOVA) for
continuous variables. Differences in dependent variables of
interest between MC + /MC - and HIV + /HIV - were tested
first using ANOVA, including the HIV, MC, and the
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interaction of the two, with Tukey Honestly Significant Difference (HSD) testing for pairwise comparisons. Groups differed slightly by race; thus, all dependent variables were also
assessed among the groups using analysis of covariance
(ANCOVA), adjusting for race. Again, the models included
HIV, MC, and their interaction, with Tukey HSD testing for
pairwise comparisons. Groups also differed by BMI, but this
was expected as BMI is reflected in MC status. Therefore, BMI
was not included in the ANCOVAs. A p-value < 0.05 was
considered statistically significant.
For variables where MC was a significant predictor, multivariable regression was used to explore which of the metabolic criteria that define MC status (i.e., BMI, fasting glucose,
fasting insulin, systolic blood pressure, diastolic blood pressure, and triglycerides) was the strongest predictor of LV
dysfunction. Models were built in a manual backward stepwise fashion, retaining variables with p < 0.05 in the final
model. Interactions of final predictors with HIV status were
also assessed to determine whether the effect of the predictors
differed by HIV status. All data are expressed as means – SD
unless specified otherwise. SAS version 9.2 (SAS, Cary, NC)
was used for all analyses.
Results
Demographics
The groups were similar in age but differed significantly
by race (Table 1). Mean CD4 count and median viral load,
time since HIV diagnosis, and time on cART were similar in
the HIV + groups (Table 1). HIV + groups tended to have a
higher percentage of tobacco users than groups without
HIV (Table 1). A greater percentage of HIV - /MC + were
taking hypertension medications than other groups and a
greater percentage of participants in the MC + groups were
taking a lipid-lowering medication than participants in the
MC - groups (Table 1).

Body composition and metabolic characteristics
BMI and DBP were greater in HIV - /MC + than all other
groups (Table 2). Fasting plasma insulin, HOMA, triglycerides, and systolic blood pressure were greater in MC + groups
than MC - groups, but did not differ by HIV status. Highdensity lipoprotein (HDL) cholesterol was lower in MC +
groups than in MC - groups. Fasting plasma glucose was
lower in HIV - /MC - than all other groups, and was lower in
HIV + /MC - than in HIV - /MC + . There were no differences
in fasting plasma total- and low-density lipoprotein cholesterol levels among groups (Table 2).
Prevalence of clinical echocardiographic abnormalities
Overall, the prevalence of systolic dysfunction was
greater in HIV + participants (15%) than in HIV - participants (4%) ( p = 0.02). The prevalence of systolic dysfunction
was similar in those who had MC (10%) than in those who
did not (11%), irrespective of HIV status ( p = 0.82). The
prevalence of systolic dysfunction tended to be greater in
HIV + /MC + (14%) and HIV + /MC - (15%) compared to
HIV - /MC + (3%) and HIV - /MC - (5%) ( p = 0.11). Overall,
there was no significant difference in prevalence of diastolic
dysfunction between HIV + participants (33%) compared to
HIV - participants (23%), regardless of MC status ( p = 0.20),
or between those with (33%) and without (25%) metabolic
complications, irrespective of HIV status ( p = 0.28). The
prevalence of diastolic dysfunction was similar among
HIV + /MC + (38%), HIV + /MC - (27%), HIV - /MC + (24%),
and HIV - /MC - (22%) ( p = 0.32). Those with HIV had a
higher prevalence of left ventricular hypertrophy (HIV + : 9%
vs. HIV - : 1%, p = 0.03) and those with MC (10%) had a
higher prevalence of left ventricular hypertrophy (LVH)
than those without MC (2%) ( p = 0.03). The prevalence of
LVH was 14% in HIV + /MC + , 3% in HIV + /MC - , 3% in
HIV - /MC + , and 0% in HIV - /MC - and tended to be higher

Table 2. Body Composition and Metabolic Characteristics
HIV Variable
BMIb
Glucose (mg/dl)c
Insulin (lU/ml)
HOMA
TG (mg/dl)
HDL (mg/dl)
Total cholesterol (mg/dl)
LDL (mg/dl)
SBP (mm Hg)
DBP (mm Hg)d
a

HIV +

ANCOVA resultsa

MC (n = 41)

MC +
(n = 37)

MC (n = 59)

MC +
(n = 64)

HIV
p

MC
p

HIV * MC
p

27.3 – 4.2
81.4 – 10.4
6.8 – 4.8
1.4 – 1.0
116.7 – 106.5
53.8 – 13.4
183.7 – 31.0
106.0 – 26.5
117.3 – 10.9
75.3 – 7.8

33.8 – 4.7
96.3 – 19.2
19.4 – 13.4
4.9 – 3.6
213.4 – 134.1
39.3 – 7.4
184.8 – 30.8
105.7 – 29.8
125.8 – 11.2
84.2 – 7.0

25.7 – 3.6
88.7 – 6.9
8.1 – 5.0
1.8 – 1.2
116.2 – 54.9
49.4 – 12.9
170.2 – 31.9
97.7 – 27.8
115.8 – 12.4
75.3 – 7.5

28.7 – 5.4
92.1 – 8.1
17.4 – 13.4
4.1 – 3.2
242.3 – 169.2
37.5 – 8.4
186.5 – 34.1
104.0 – 32.0
125.3 – 13.5
77.6 – 9.7

< 0.001
0.315
0.766
0.555
0.251
0.009
0.185
0.195
0.411
0.002

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.059
0.441
< 0.001
< 0.001

0.005
0.001
0.248
0.081
0.366
0.489
0.113
0.463
0.812
0.005

Adjusted for race.
Significant pairwise comparisons for BMI: HIV - /MC - vs. HIV - /MC + p < 0.001; HIV - /MC + vs. HIV + /MC - p < 0.001; HIV - /MC + vs.
HIV + /MC + p < 0.001; HIV + /MC - vs. HIV + /MC + p = 0.001.
c
Significant pairwise comparisons for glucose: HIV - /MC - vs. HIV - /MC + , p < 0.001; HIV - /MC - vs. HIV + /MC - p = 0.008; HIV - /MC vs. HIV + /MC + p < 0.001; HIV - /MC + vs. HIV + /MC - p = 0.013.
d
Significant pairwise comparisons for DBP: HIV - /MC - vs. HIV - /MC + p < 0.001; HIV - /MC + vs. HIV + /MC - p < 0.001; HIV - /MC + vs.
HIV + /MC + p < 0.001.
HIV, human immunodeficiency virus; MC, metabolic complications; BMI, body mass index; TG, triglyceride; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure.
b
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Table 3. Echocardiographic Parameters
HIV Variable

MC (n = 41)

BSA (m2)
2.0 – 0.3
HR (bpm)
63.1 – 9.7
LV structure
LVM-mm (g)
166.4 – 38.0
LVMI (g/m2)
83.3 – 12.8
LV systolic function
EF (%)
62 – 6
FS (%)
31.3 – 6.5
LVET (ms)
300.8 – 21.8
S¢ (cm/s)
8.9 – 1.3
LV diastolic function
E-wave (cm/s)
71.6 – 11.5
E/A ratio
1.59 – 0.41
E¢ (cm/s)
13.1 – 2.4
E/E¢
5.6 – 1.0
DT (ms)
199.2 – 36.2
IVRT (ms)
82.1 – 16.0

HIV +

ANCOVA resultsa

MC +
(n = 37)

MC (n = 59)

MC +
(n = 64)

HIV
p

MC
p

HIV*MC
p

2.2 – 0.2
67.7 – 11.5

2.0 – 0.3
64.6 – 12.2

2.1 – 0.4
65.9 – 12.3

0.039
0.656

< 0.001
0.059

0.203
0.288

206.9 – 49.6
91.7 – 17.3

183.2 – 38.8
93.4 – 16.4

200.2 – 47.8
95.8 – 21.7

0.615
0.007

< 0.001
0.045

0.058
0.262

62 – 6
33.1 – 4.8
291.2 – 28.7
8.4 – 1.5

59 – 6
33.7 – 6.2
291.1 – 32.9
8.1 – 1.0

61 – 7
34.7 – 6.0
283.5 – 33.9
8.1 – 0.9

0.022
0.093
0.056
0.003

0.405
0.161
0.060
0.133

0.535
0.532
0.827
0.174

72.0 – 17.2
1.51 – 0.48
12.0 – 2.3
6.1 – 1.3
199.3 – 38.0
88.4 – 16.5

68.9 – 15.6
1.52 – 0.52
12.4 – 2.3
5.6 – 1.3
199.7 – 36.9
87.8 – 15.7

67.4 – 15.4
1.29 – 0.44
11.6 – 2.3
5.9 – 1.4
202.9 – 35.6
87.7 – 13.0

0.035
0.026
0.105
0.533
0.556
0.237

0.950
0.027
0.005
0.020
0.832
0.173

0.583
0.230
0.795
0.520
0.739
0.149

a
Adjusted for race.
HIV, human immunodeficiency virus; MC, metabolic complications; BSA, body surface area; HR, heart rate; LVM-mm, left ventricular
mass measured by M-mode; LVMI, left ventricular mass index (LVM/BSA); EF, ejection fraction; LVET, left ventricular ejection time; FS,
fractional shortening; S¢, systolic myocardial velocity averaged from the lateral wall and septum; E¢, myocardial velocity during early diastole
averaged from the lateral wall and septum; DT, deceleration time; IVRT, isovolumic contraction time.

in HIV + /MC + than HIV + /MC - ( p = 0.06), HIV - /MC +
( p = 0.09), and HIV - /MC - ( p = 0.01).
LV structure and function
There were significant independent effects of HIV and MC
on LV mass index. LV mass index was higher in HIV + participants and for MC + participants (Table 3). HIV had a significant or trended toward a significant independent negative
effect on several systolic function variables including ejection
fraction, fractional shortening, LV ejection time, and annular
velocity measured during systole (Table 3). Both HIV infection and the presence of MC had significant or trended toward
having an independent negative effect on several indices reflective of diastolic function, e.g., lower E/A ratio (Table 3)
and lower early diastolic mitral annular velocity during diastole (E¢) in HIV + groups and in MC + groups. However,
there was no interaction effect of HIV and MC for any systolic
or diastolic variable (i.e., effects of HIV did not significantly
differ by MC status).
Components of MC as predictors of LV function
In backward step-wise multivariable regression models of
LV structure and function, HIV status and components of MC
were used as predictors (i.e., BMI, fasting glucose, fasting
insulin, systolic blood pressure, diastolic blood pressure, triglyceride) (Table 4). For prediction of reduced annular velocity during systole (S¢), higher fasting glucose and HIV
infection were independent predictors; interactions with HIV
were not significant. For prediction of annular velocity during
diastole (E¢), higher fasting insulin and HIV infection independently predicted reduced E¢. In a similar model, higher
fasting insulin, diastolic blood pressure, and HIV infection

remained independently associated with a reduced E/A ratio.
The interactions of fasting glucose and diastolic blood pressure with HIV were not significant. Finally, in the model
predicting LV mass index, systolic blood pressure, BMI, HIV
infection, and the interaction of HIV infection and BMI remained in the final model. The interaction of BMI and HIV
suggested that a negative association of BMI with LV mass
index was largely confined in HIV + participants, but not in
HIV - participants. There were no significant associations
with cART class (PI vs. no-PI) and LV outcome variables in
HIV + participants.
Discussion
This is the first study to examine the potential relationships
among well-controlled HIV infection and metabolic risk factors for cardiovascular disease and LV function, and compare
these to HIV-negative men and women with and without
similar metabolic risk factors. The main finding was that HIV
infection and metabolic risk factors have independent
negative associations with diastolic function. However, wellcontrolled HIV infection does not act additively or synergistically with indices of metabolic risk that adversely affect
diastolic function. In addition, it appears that HIV also has an
independent negative association with systolic function and
LV mass. An adverse relationship of HIV infection with LV
function and mass has been previously reported in primate
models of simian immunodeficiency (SIV) and in humans
with HIV.9,16,17 Furthermore, other studies have shown that
metabolic risk factors have an independent negative relationship with LV function and mass in HIV-negative individuals.27–29 However, no previous study has examined the
potential additive effect of these variables on the relationship
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Table 4. Regression Results for Components of Metabolic Complications as Predictors
of Left Ventricular Function

Dependent variable
Annular velocity during systole (S¢)
Annular velocity during diastole (E¢)

E/A ratio

LVMI

Independent variables
Fasting glucose
HIV infection (positive
Fasting insulin
DBP
HIV infection (positive
Fasting insulin
DBP
HIV infection (positive
SBP
BMI
HIV infection (positive
HIV infection * BMI

versus negative)

versus negative)

versus negative)

versus negative)

b

SE

p

- 0.0001
- 0.006
- 0.0004
- 0.0008
- 0.008
- 0.0077
- 0.0137
- 0.186
0.3187
0.4369
51.167
- 1.549

0.0001
0.002
0.0001
0.0002
0.003
0.0029
0.0038
0.068
0.0972
0.3691
14.152
0.479

0.037
0.001
0.005
< 0.001
0.015
0.009
< 0.001
0.007
0.001
0.238
< 0.001
0.001

Components of metabolic complications used as predictors were BMI, fasting glucose, fasting insulin, SBP, DBP, and TG. Results shown are
from backward step-wise multivariable regression, retaining variables with p < 0.05 in the final model.
S¢, systolic myocardial velocity averaged from the lateral wall and septum; HIV, human immunodeficiency virus; E¢, myocardial velocity
during early diastole averaged from the lateral wall and septum; DBP, diastolic blood pressure; LVMI, left ventricular mass index; SBP,
systolic blood pressure; BMI, body mass index.

with LV function in people living with well-controlled HIV.
Our data confirm previous reports from SIV-infected nonhuman primates and HIV-infected humans that demonstrated the adverse relationship among these chronic
infections and LV function.
The finding of no additional negative effect of HIV infection
on the relationship with diastolic function and LV mass indexed for body surface area over the detrimental effects of
metabolic complications was surprising and contrary to our
hypothesis. It is unclear how the presence of metabolic complications mediates impaired diastolic function. One metabolic
complication, obesity, is significantly related to diastolic dysfunction and increased LV mass.46 Specifically, there is impaired LV relaxation and increased LV end-diastolic pressure
with increased BMI.46 Although the mechanisms are not
completely clear, increased levels of reactive oxygen species51,52 as well as lipid-induced apoptosis53 have been implicated in the development of obesity-related impaired LV
relaxation. In the current study, HIV - participants with metabolic risk factors had greater BMI than HIV + participants with
metabolic complications. Perhaps if the degree of obesity was
identically matched between metabolically complicated
groups, then greater impairments in LV function and mass
may have been detected in HIV + participants. Also, in the
current study, we found a relationship between higher plasma
insulin (along with diastolic blood pressure) and lower diastolic function among all participants (and in separate HIV +
and HIV - only analyses, data not shown) indicating that insulin resistance may play a role in diastolic dysfunction regardless of HIV infection. We previously reported
relationships between myocardial insulin resistance and reduced diastolic function in a smaller study of HIV + men.54 A
positive association between insulin resistance and diastolic
dysfunction has also been shown in HIV - individuals.38
However, the mechanism for insulin resistance-mediated
diastolic dysfunction in humans with HIV remains to be
elucidated.
In the present study, HIV, and less commonly peripheral
metabolic risk factors, were associated with greater abnor-

malities in systolic and diastolic function. With the exception
of the E/A ratio, none of the measured parameters of systolic
and diastolic function was significantly predicted by both
HIV and metabolic risk factors; therefore, there is little evidence for an additive or synergistic effect of HIV with the
presence of metabolic risk factors on LV function. Although
not fully understood, it appears that HIV replication16 may
mediate impaired diastolic dysfunction through the viral
glycoprotein 12055,56 and the CXCR4-iPLA2-p38 mitogenactivated (MAP) kinase-troponin I inflammatory signaling
pathway.56–58 It is possible that peripheral metabolic complications and HIV may mediate diastolic dysfunction
through a similar inflammatory pathway and therefore that is
the reason we did not see an additive effect of metabolic
complications with HIV in the current study. Metabolic syndrome is a proinflammatory state59 and the MAP kinase
pathway60 and other G-protein-associated pathways61 have
been implicated in playing a role in non-HIV metabolic syndrome and CVD. However, we did not measure serum inflammatory cytokines or obtain myocardial biopsies to
examine the effect of these inflammatory pathways on LV
function in the current study. In addition, 86% of the current
participants were virologically suppressed with cART.
There is some previous evidence that HIV mediates systolic
dysfunction. Systolic dysfunction was found in animal models that expressed increased amounts of HIV proteins62–64 and
in patients with advanced disease (i.e., increased plasma viremia)65–67; however, it is unclear if HIV-associated systolic
dysfunction is mediated through a pathway similar to HIVassociated diastolic dysfunction. Additional research in this
area, especially in HIV-infected individuals with HIV suppression, is warranted.
LV mass was also independently associated with both HIV
infection and the presence of metabolic complications. The
association of LV mass with metabolic complications is in
agreement with previous studies in HIV - individuals.68
However, the presence of both HIV and metabolic complications did not result in greater increases in LV mass. The
finding of an independent effect of HIV is in agreement with
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Hsue et al.9 who reported that HIV infection was associated
with both greater LV mass and diastolic dysfunction. However, the authors did not examine the relationship between
individual metabolic risk factors and LV mass and function.
There is a well-established relationship between obesity and
increased LV mass.69
It is possible that no differences in LV mass index were
found between HIV + and HIV - groups with metabolic
complications because HIV - participants with metabolic
complications were significantly more obese than HIV +
participants with metabolic complications. However, in the
current study, the relationship between higher BMI and increased LV mass index appeared to be present only in HIV +
individuals; therefore the presence of increased obesity in
the HIV - group may not have obscured potential differences in LV mass between groups. The presence of increased
LV mass (i.e., LV hypertrophy) is an important clinical
problem as it increases the risk for cardiovascular morbidity
and mortality, including the development of both systolic
and diastolic dysfunction, and progression to heart failure.70
Therefore, it appears that LV mass should be monitored in
HIV + individuals with well-controlled HIV infection with a
potential focus on modulation of obesity and elevated
blood pressure, two well-established risk factors for increased LV mass.71
Although moderate and severe LV systolic dysfunction was
not present in these participants, diastolic abnormalities are
clinically important. They play a fundamental role in the development of heart failure, as they precede systolic failure in as
many as 40% of cases.72,73 Diastolic dysfunction has a marked
effect on exercise tolerance and quality of life,74 and when it
progresses to heart failure with preserved ejection fraction
(HFpEF, also known as diastolic heart failure), it has a mortality similar to systolic heart failure.74 HFpEF is defined by
clinical signs or symptoms of heart failure, evidence of normal
left ventricular function, and evidence of diastolic dysfunction.75 Although mortality is lower in HFpEF than in those
with heart failure and reduced ejection fraction, the overall
absolute number of deaths in the general population attributable to HFpEF is likely higher due to the aging population.76
In addition, the presence of insulin resistance is associated
with a worse prognosis and increased risk for cardiovascularrelated death in those with HFpEF.77 Therefore, since 33% of
HIV-infected people with well-controlled viremia (as in the
current study) have evidence of diastolic dysfunction, close
monitoring of LV function appears to be warranted in HIV +
men and women with well-controlled HIV infection.
Women were underrepresented in this study and future
studies should examine differences in LV function and mass
between genders. Because this was a cross-sectional study
causality cannot be confirmed. Our conclusions cannot be extended to HIV + individuals not taking cART or those with
greater plasma viremia. Groups were not perfectly matched on
metabolic risk factors; HIV - individuals with metabolic complications had greater BMI, plasma glucose, and diastolic blood
pressure than HIV + participants with metabolic complications.
Conclusions
Regardless of HIV status, men and women with metabolic
risk factors had worse indices of LV diastolic function in
comparison to those without risk factors. Although both the
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presence of metabolic risk factors and HIV infection were
associated with lower diastolic function, there was no additive negative effect of HIV on diastolic function beyond the
effect of metabolic risk factors. Also, HIV was independently
associated with lower systolic function. Clinical monitoring
of LV function and implementation of interventions to improve metabolic health and cardiovascular risk in individuals
with metabolic risk factors, regardless of HIV status, are
warranted.
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